Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 87.68 CHF 1.11%
Market Cap: 171.5B CHF
Have any thoughts about
Novartis AG?
Write Note
Section:
 

Relative Value

The Relative Value of one NOVN stock under the Base Case scenario is 97.87 CHF. Compared to the current market price of 87.68 CHF, Novartis AG is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVN Relative Value
Base Case
97.87 CHF
Undervaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
15
vs Industry
29
Median 3Y
3.4
Median 5Y
3.3
Industry
2.5
Forward
3.7
More Details
10.8
P/E
P/E
Price to Earnings
10.8
vs History
76
vs Industry
33
Median 3Y
13
Median 5Y
14.2
Industry
21.8
Forward
11.3
More Details
11.5
P/OCF
P/OCF
Price to OCF
11.5
vs History
65
vs Industry
29
Median 3Y
12.1
Median 5Y
12
Industry
16.1
More Details
10.9
P/FCFE
P/FCFE
Price to FCFE
10.9
vs History
79
vs Industry
22
Median 3Y
22.1
Median 5Y
19.9
Industry
23.8
More Details
4.8
P/B
P/B
Price to Book Value
4.8
vs History
15
vs Industry
14
Median 3Y
3.7
Median 5Y
3
Industry
2.1
More Details
4
EV/S
EV/S
Enterprise Value to Sales
4
vs History
14
vs Industry
26
Median 3Y
3.6
Median 5Y
3.6
Industry
2.7
Forward
3.9
More Details
5.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.3
vs History
17
vs Industry
35
Median 3Y
4.8
Median 5Y
5
Industry
5.2
More Details
9.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.4
vs History
63
vs Industry
33
Median 3Y
9.4
Median 5Y
9.7
Industry
13.5
Forward
9.8
More Details
13.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.1
vs History
76
vs Industry
28
Median 3Y
13.7
Median 5Y
14.7
Industry
16.8
Forward
11.4
More Details
12
EV/OCF
EV/OCF
Enterprise Value to OCF
12
vs History
68
vs Industry
28
Median 3Y
12.5
Median 5Y
12.6
Industry
15.2
More Details
15.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.2
vs History
53
vs Industry
21
Median 3Y
15.4
Median 5Y
15.4
Industry
19.3
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
15
vs Industry
29
Median 3Y
2.1
Median 5Y
1.7
Industry
1.9
More Details

Multiples Across Competitors

NOVN Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
162.1B GBP 4.1 31.5 169.4 253.9
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
IE
Endo International PLC
LSE:0Y5F
147.1B USD 63.5 -50.3 236.2 592.2
P/S Multiple
Revenue Growth P/S to Growth
CH
Novartis AG
SIX:NOVN
Average P/S: 382 947.7
3.8
17%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
IE
E
Endo International PLC
LSE:0Y5F
63.5
N/A N/A
P/E Multiple
Earnings Growth P/E to Growth
CH
Novartis AG
SIX:NOVN
Average P/E: 32.4
10.8
31%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -50.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Novartis AG
SIX:NOVN
Average EV/EBITDA: 437.2
9.4
8%
1.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
IE
E
Endo International PLC
LSE:0Y5F
236.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Novartis AG
SIX:NOVN
Average EV/EBIT: 1 869.4
13.1
58%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
1.9
US
Pfizer Inc
NYSE:PFE
16
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

See Also

Summary
NOVN intrinsic value, competitors valuation, and company profile.
DCF Valuation
NOVN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NOVN stock valuation using valuation multiples.
Wall Street Estimates
NOVN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NOVN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.